

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**  
**AS AT AND FOR SIX MONTH PERIOD ENDED 31 DECEMBER 2024**  
**(HALF YEARLY)**

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Condensed Consolidated Statement of Financial Position (Unaudited)**  
**As at 31 December 2024**

Particulars	Notes	Amount In BDT	
		31-Dec-24	30-Jun-24
<b>Assets</b>			
<b>Non-Current Assets</b>		<b>37,259,895,452</b>	<b>36,332,123,652</b>
Property, Plant and Equipment	6	20,783,100,880	21,077,115,349
Right of use Assets	7	42,729,124	24,361,873
Capital Work in Progress	8	8,609,294,688	7,163,967,741
Investment in Associates	10	1,890,281,000	2,128,615,000
Other Investments	11	5,934,489,760	5,938,063,689
<b>Current Assets</b>		<b>17,029,509,630</b>	<b>16,853,384,669</b>
Inventories	12	1,572,187,325	1,699,322,929
Trade and Other Receivables	13	14,445,909,783	13,915,714,014
Advances, Deposits & Prepayments	14	863,154,020	1,044,796,936
Fixed Deposit with Banks	15	51,029,213	45,820,338
Cash and Cash Equivalents	16	97,229,289	147,730,452
<b>Total Assets</b>		<b>54,289,405,082</b>	<b>53,185,508,321</b>
<b>Shareholders' Equity and Liabilities</b>			
<b>Shareholders' Equity</b>		<b>21,018,005,605</b>	<b>21,539,576,338</b>
Share Capital	17	2,340,000,000	2,340,000,000
Share Premium		8,016,892,026	8,016,892,026
Reserves	18	3,438,766,706	3,683,345,150
Retained Earnings	19	7,222,346,873	7,499,339,162
Non - Controlling Interest	20	1,504,642,633	1,543,272,725
<b>Total Equity</b>		<b>22,522,648,238</b>	<b>23,082,849,063</b>
<b>Non-Current Liabilities</b>		<b>23,217,784,540</b>	<b>22,336,273,004</b>
Provision for Decommissioning of Assets		143,405,563	143,405,563
Long Term Loan	21	22,684,864,092	21,863,720,817
Lease Obligation	22	30,117,504	13,714,468
Deferred Tax Liability	23	359,397,380	315,432,156
<b>Current Liabilities</b>		<b>8,548,972,305</b>	<b>7,766,386,253</b>
Current portion of Long Term loan	21.1	67,349,871	67,349,871
Current Portion of Lease Obligation	22.1	15,407,808	13,943,551
Short term loans	24	522,430,128	556,177,120
Trade and Other Payables	25	7,049,143,737	6,463,692,757
Employee Benefits	26	152,348,043	147,234,452
Unclaimed/Unpaid Dividend		284,922,619	58,675,647
Accrued Expenses	27	457,370,098	459,312,854
<b>Total Equity &amp; Liabilities</b>		<b>54,289,405,082</b>	<b>53,185,508,321</b>
<b>Number of Shares Used to Compute NAV</b>		<b>234,000,000</b>	<b>234,000,000</b>
<b>Net Asset Value (NAV) Including Revaluation Surplus</b>	33	<b>89.82</b>	<b>92.05</b>
<b>Net Asset Value (NAV) Excluding Revaluation Surplus</b>		<b>82.06</b>	<b>84.27</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION PHARMA LIMITED**  
**Condensed Statement of Financial Position (Unaudited)**  
**As at 31 December 2024**

Particulars	Notes	Amount In BDT	
		31-Dec-24	30-Jun-24
<b>Assets</b>			
<b>Non-Current Assets</b>		<b>28,711,713,350</b>	<b>27,735,689,008</b>
Property, Plant and Equipment	6a	15,019,418,778	15,265,180,705
Right of use Assets	7	42,729,124	24,361,873
Capital Work in Progress	8	8,609,294,688	7,163,967,741
Investment in Subsidiaries	9	1,017,000,000	1,017,000,000
Investment in Associate	10	1,890,281,000	2,128,615,000
Other Investments	11a	2,132,989,760	2,136,563,689
<b>Current Assets</b>		<b>10,362,723,370</b>	<b>10,716,440,347</b>
Inventories	12a	604,539,450	637,639,101
Trade and Other Receivables	13a	8,846,858,502	8,944,679,482
Advances, Deposits & Prepayments	14a	778,339,671	959,959,975
Fixed Deposit with Banks	15	51,029,213	45,820,338
Cash and Cash Equivalents	16a	81,956,534	128,341,450
<b>Total Assets</b>		<b>39,074,436,720</b>	<b>38,452,129,354</b>
<b>Shareholders' Equity and Liabilities</b>			
<b>Shareholders' Equity</b>		<b>14,229,806,805</b>	<b>14,652,306,216</b>
Share Capital	17	2,340,000,000	2,340,000,000
Share Premium		8,016,892,026	8,016,892,026
Reserves	18a	3,090,657,122	3,333,848,346
Retained Earnings	19a	782,257,658	961,565,844
<b>Non-current Liabilities</b>		<b>23,074,378,977</b>	<b>22,192,867,441</b>
Long term loan	21a	22,684,864,092	21,863,720,817
Lease obligation	22	30,117,504	13,714,468
Deferred tax liability	23	359,397,380	315,432,156
<b>Current Liabilities</b>		<b>1,770,250,938</b>	<b>1,606,955,697</b>
Current portion long term loan	21a.1	67,349,871	67,349,871
Current portion of finance lease obligation	22.1	15,407,808	13,943,551
Short term loans	24	522,430,128	556,177,120
Trade and other payables	25a	415,539,672	450,267,403
Employee benefits	26a	55,797,731	50,684,141
Unclaimed/Unpaid Dividend		284,922,619	58,675,647
Accrued expenses	27a	408,803,108	409,857,964
<b>Total Equity &amp; Liabilities</b>		<b>39,074,436,720</b>	<b>38,452,129,354</b>
<b>Number of Shares Used to Compute NAV</b>		<b>234,000,000</b>	<b>234,000,000</b>
<b>Net Asset Value (NAV) Including Revaluation Surplus</b>	33a	<b>60.81</b>	<b>62.62</b>
<b>Net Asset Value (NAV) Excluding Revaluation Surplus</b>		<b>55.03</b>	<b>56.83</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income ( Unaudited)**  
**For Six Month Period Ended 31 December 2024**

Particulars	Notes	Amount In BDT			
		July 2024 to December 2024	July 2023 to December 2023	October to December 2024	October to December 2023
Revenue from Net Sales	28	2,506,936,871	5,745,198,724	860,395,059	2,135,546,884
Cost of Goods Sold		(825,231,811)	(886,908,455)	(446,833,105)	(467,919,379)
Cost of Power Generation		(852,034,685)	(3,647,355,361)	(32,601,981)	(1,044,860,747)
<b>Gross Profit</b>		<b>829,670,376</b>	<b>1,210,934,909</b>	<b>380,959,973</b>	<b>622,766,758</b>
<b>Operating Expenses</b>		<b>(692,641,366)</b>	<b>(796,062,806)</b>	<b>(374,125,457)</b>	<b>(443,545,600)</b>
General & Administrative Expenses		(259,937,431)	(295,834,056)	(141,844,356)	(167,058,769)
Selling & Distribution Expenses		(432,703,935)	(500,228,750)	(232,281,101)	(276,486,831)
<b>Profit from Operation</b>		<b>137,029,010</b>	<b>414,872,103</b>	<b>6,834,517</b>	<b>179,221,158</b>
Financial Expenses	29	(175,642,071)	(48,891,937)	(120,640,549)	(32,483,272)
Non Operating Income/ (Loss)	30	8,297,053	13,785,867	6,669,449	9,922,290
<b>Net Profit from Operation</b>		<b>(30,316,008)</b>	<b>379,766,032</b>	<b>(107,136,583)</b>	<b>156,660,176</b>
Workers Profit Participation Fund		(5,113,591)	(18,084,097)	(262,578)	(7,460,008)
<b>Net Profit before Tax</b>		<b>(35,429,599)</b>	<b>361,681,936</b>	<b>(107,399,161)</b>	<b>149,200,168</b>
<b>Income Tax</b>		<b>(54,959,125)</b>	<b>(57,953,581)</b>	<b>(30,395,239)</b>	<b>(22,822,127)</b>
Current Tax (Expenses)/Income	31	(10,214,073)	(69,075,948)	(5,211,767)	(28,539,972)
Deferred Tax (Expenses)/Income		(44,745,051)	11,122,367	(25,183,473)	5,717,844
<b>Net Profit after Tax</b>		<b>(90,388,723)</b>	<b>303,728,355</b>	<b>(137,794,400)</b>	<b>126,378,040</b>
Share of Profit from Associate		4,562,900	4,695,800	2,170,700	1,781,923
<b>Net Profit</b>		<b>(85,825,823)</b>	<b>308,424,155</b>	<b>(135,623,699)</b>	<b>128,159,962</b>
Less: Non Controlling Interest (share of operating profit)		38,630,093	(21,506,433)	33,032,297	(17,976,576)
<b>Net Profit after Tax before Other Comprehensive Income</b>		<b>(47,195,730)</b>	<b>286,917,721</b>	<b>(102,591,402)</b>	<b>110,183,386</b>
<b>Other Comprehensive Income</b>		<b>(240,376,353)</b>	<b>108,393,555</b>	<b>322,264,715</b>	<b>130,712,488</b>
Fair Value Gain of Marketable Securities		(3,575,279)	(1,855,550)	(1,041,951)	(1,695,860)
Fair Value Gain on Investment in Associate		(237,750,163)	109,139,217	322,843,028	131,368,600
Share of Other Comprehensive Income		169,263	458,983	148,272	635,477
Deferred tax Income (Expenses) on Revaluation Surplus of PPE & Fair Value Changes of Marketable securities		779,826	650,905	315,367	404,271
<b>Total Comprehensive Income Attributable to Ordinary Shareholders</b>		<b>(287,572,083)</b>	<b>395,311,276</b>	<b>219,673,313</b>	<b>240,895,875</b>
<b>Number of Shares Used to Compute EPS</b>		<b>234,000,000</b>	<b>234,000,000</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Earnings Per Share (EPS)</b>	32	<b>(0.20)</b>	<b>1.23</b>	<b>(0.44)</b>	<b>0.47</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION PHARMA LIMITED**  
**Condensed Statement of Profit or Loss and Other Comprehensive Income ( Unaudited)**  
**For Six Month Period Ended 31 December 2024**

Particulars	Notes	Amount In BDT			
		July 2024 to December 2024	July 2023 to December 2023	October to December 2024	October to December 2023
Revenue from Net Sales	28.a	1,689,366,093	1,949,599,977	858,904,418	1,018,114,540
Cost of Goods Sold		(825,231,811)	(886,908,455)	(446,833,105)	(467,919,379)
<b>Gross Profit</b>		<b>864,134,282</b>	<b>1,062,691,522</b>	<b>412,071,313</b>	<b>550,195,162</b>
<b>Operating Expenses</b>		<b>(664,702,435)</b>	<b>(765,934,473)</b>	<b>(362,856,372)</b>	<b>(429,456,054)</b>
General & Administrative Expenses		(231,998,501)	(265,705,723)	(130,575,271)	(152,969,223)
Selling & Distribution Expenses		(432,703,935)	(500,228,750)	(232,281,101)	(276,486,831)
<b>Profit from Operation</b>		<b>199,431,847</b>	<b>296,757,049</b>	<b>49,214,942</b>	<b>120,739,108</b>
Financial Expenses	29.a	(100,343,492)	(30,114,862)	(50,370,252)	(14,218,460)
Non Operating Income/ (Loss)	30.a	8,297,053	13,785,867	6,669,449	9,922,290
<b>Net Profit from Operation</b>		<b>107,385,407</b>	<b>280,428,054</b>	<b>5,514,139</b>	<b>116,442,938</b>
Workers Profit Participation Fund		(5,113,591)	(13,353,717)	(262,578)	(5,544,902)
<b>Net Profit before Tax</b>		<b>102,271,817</b>	<b>267,074,338</b>	<b>5,251,560</b>	<b>110,898,036</b>
<b>Income Tax</b>		<b>(54,959,125)</b>	<b>(57,953,581)</b>	<b>(30,395,239)</b>	<b>(22,822,127)</b>
Current Tax (Expenses)/Income	31	(10,214,073)	(69,075,948)	(5,211,767)	(28,539,972)
Deferred Tax (Expenses)/Income		(44,745,051)	11,122,367	(25,183,473)	5,717,844
<b>Net Profit after Tax</b>		<b>47,312,692</b>	<b>209,120,757</b>	<b>(25,143,679)</b>	<b>88,075,909</b>
Share of Profit from Associates		4,562,900	4,695,800	2,170,700	1,781,923
<b>Net Profit after Tax before Other Comprehensive Income</b>		<b>51,875,592</b>	<b>213,816,557</b>	<b>(22,972,979)</b>	<b>89,857,832</b>
<b>Other Comprehensive Income</b>		<b>(240,376,353)</b>	<b>108,393,555</b>	<b>322,264,715</b>	<b>130,712,488</b>
Fair Value Gain of Marketable Securities		(3,575,279)	(1,855,550)	(1,041,951)	(1,695,860)
Fair Value Gain on Investment in Associate		(237,750,163)	109,139,217	322,843,028	131,368,600
Share of Other Comprehensive Income		169,263	458,983	148,272	635,477
Deferred tax Income (Expenses) on Revaluation Surplus of PPE & Fair Value Changes of Marketable securities		779,826	650,905	315,367	404,271
<b>Total Comprehensive Income attribute to Ordinary Shareholders</b>		<b>(188,500,761)</b>	<b>322,210,112</b>	<b>299,291,736</b>	<b>220,570,320</b>
<b>Number of Shares Used to Compute EPS</b>		<b>234,000,000</b>	<b>234,000,000</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Earnings Per Share (EPS)</b>	32.a	<b>0.22</b>	<b>0.91</b>	<b>(0.10)</b>	<b>0.38</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Condensed Consolidated Statement of Changes in Equity (Unaudited)**  
**For Six Month Period Ended 31 December 2024**

Amount in BDT

Particulars	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total	Non controlling Interest	Total
<b>Balance at 01 July 2024</b>	2,340,000,000	8,016,892,026	3,683,345,150	7,499,339,162	21,539,576,338	1,543,272,725	23,082,849,063
Net Profit after Tax	-	-	-	(47,195,730)	(47,195,730)	(38,630,093)	(85,825,823)
Cash Dividend for the year 2023-2024				(234,000,000)	(234,000,000)		(234,000,000)
Fair Value Gain / (Loss) on Investment in Associate			(237,750,163)	-	(237,750,163)	-	(237,750,163)
Fair Value (Loss)/Gain on Marketable Securities			(3,575,279)	-	(3,575,279)	-	(3,575,279)
Adjustment for sale of Mkt. Securities			1,350	-	1,350	-	1,350
Share of Other Comprehensive Income			169,263	-	169,263	-	169,263
Adjustment of Deferred tax on Revaluation Surplus			779,826	-	779,826	-	779,826
Depreciation on Revaluation Surplus			(4,203,441)	4,203,441	-	-	-
<b>Balance at 31 December 2024</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>3,438,766,706</b>	<b>7,222,346,873</b>	<b>21,018,005,605</b>	<b>1,504,642,633</b>	<b>22,522,648,238</b>

**For Six Month Period Ended 31 December 2023**

Particulars	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total	Non controlling Interest	Total
<b>Balance at 01 July 2023</b>	2,340,000,000	8,016,892,026	3,067,212,663	7,400,327,363	20,824,432,052	1,509,624,870	22,334,056,922
Net Profit after Tax	-	-	-	286,917,721	286,917,721	21,506,433	308,424,155
Cash Dividend for the year 2022-2023				(234,000,000)	(234,000,000)		(234,000,000)
Fair Value Gain / (Loss) on Investment in Associate			109,139,217	-	109,139,217	-	109,139,217
Fair Value (Loss)/Gain on Marketable Securities			(1,855,550)	-	(1,855,550)	-	(1,855,550)
Adjustment for sale of Mkt. Securities			40,203	-	40,203	-	40,203
Share of Other Comprehensive Income			458,983	-	458,983	-	458,983
Adjustment of Deferred tax on Revaluation Surplus			650,905	-	650,905	-	650,905
Adjustment for Right of use Assets				690,826	690,826	-	690,826
Depreciation on Revaluation Surplus			(7,020,254)	7,020,254	-	-	-
<b>Balance at 31 December 2023</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>3,168,626,167</b>	<b>7,460,956,166</b>	<b>20,986,474,358</b>	<b>1,531,131,303</b>	<b>22,517,605,661</b>

Sd-  
Chairman

Sd-  
Managing Director

Sd-  
Director

Sd-  
Chief Financial Officer

Sd-  
Company Secretary

**ORION PHARMA LIMITED**  
**Condensed Statement of Changes in Equity (Unaudited)**  
**For Six Month Period Ended 31 December 2024**

Particulars	Amount in BDT				
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
<b>Balance at 01 July 2024</b>	2,340,000,000	8,016,892,026	3,333,848,346	961,565,844	14,652,306,216
Net Profit after Tax	-	-	-	51,875,592	51,875,592
Cash Dividend for the year 2023-2024	-	-	-	(234,000,000)	(234,000,000)
Fair Value Gain / (Loss) on Investment in Associate	-	-	(237,750,163)	-	(237,750,163)
Fair Value (Loss)/Gain on Marketable Securities	-	-	(3,575,279)	-	(3,575,279)
Adjustment for sale of Mkt. Securities	-	-	1,350	-	1,350
Share of Other Comprehensive Income	-	-	169,263	-	169,263
Adjustment of Deferred tax on Revaluation Surplus	-	-	779,826	-	779,826
Depreciation on Revaluation Surplus	-	-	(2,816,222)	2,816,222	-
<b>Balance at 31 December 2024</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>3,090,657,122</b>	<b>782,257,658</b>	<b>14,229,806,805</b>

**For Six Month Period Ended 31 December 2023**

Particulars	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
<b>Balance at 01 July 2023</b>	2,340,000,000	8,016,892,026	2,709,933,620	973,857,096	14,040,682,742
Net Profit after Tax	-	-	-	213,816,557	213,816,557
Cash Dividend for the year 2022-2023	-	-	-	(234,000,000)	(234,000,000)
Fair Value Gain / (Loss) on Investment in Associate	-	-	109,139,217	-	109,139,217
Fair Value (Loss)/Gain on Marketable Securities	-	-	(1,855,550)	-	(1,855,550)
Adjustment for sale of Mkt. Securities	-	-	40,203	-	40,203
Share of Other Comprehensive Income	-	-	458,983	-	458,983
Adjustment of Deferred tax on Revaluation Surplus	-	-	650,905	-	650,905
Adjustment for Right of use Assets	-	-	-	690,826	690,826
Depreciation on Revaluation Surplus	-	-	(3,129,135)	3,129,135	-
<b>Balance at 31 December 2023</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>2,815,238,243</b>	<b>957,493,614</b>	<b>14,129,623,883</b>

**Sd-  
Chairman**

**Sd-  
Managing Director**

**Sd-  
Director**

**Sd-  
Chief Financial Officer**

**Sd-  
Company Secretary**

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Condensed Consolidated Statement of Cash Flows ( Unaudited)**  
**For Six Month Period Ended 31 December 2024**

Particulars	Amount In BDT	
	July 2024 to December 2024	July 2023 to December 2023
<b>A. Cash Flows from Operating Activities :</b>		
Cash Received from Customers	2,332,926,079	5,475,900,760
Cash Paid to Suppliers	(884,763,705)	(4,075,508,237)
Cash Payment for Operating Expenses	(422,706,568)	(652,623,718)
<b>Cash Generated from Operation</b>	<b>1,025,455,806</b>	<b>747,768,805</b>
Income Taxes Paid	(28,090,238)	(120,185,674)
<b>Net Cash Generated/(Used) from Operating Activities</b>	<b>997,365,568</b>	<b>627,583,130</b>
<b>B. Cash Flows from Investing Activities :</b>		
Acquisition of Property, Plant & Equipment	(60,668,840)	(11,898,637)
Capital Work in Progress	(1,445,326,947)	(1,338,437,925)
Investment in Subsidiaries, Associate & Others	6,218,032	412,473,979
Interest, Dividend & Other Income	8,297,053	13,785,866
<b>Net Cash Received/(Used) from Investing Activities</b>	<b>(1,491,480,702)</b>	<b>(924,076,716)</b>
<b>C. Cash Flows from Financing Activities :</b>		
Long Term Loan Received/ (Repaid)	821,143,274	(2,035,577,824)
Short Term Loan Received/ (Repaid)	(212,001,498)	2,405,755,682
Lease obligation	17,867,293	(12,936,354)
Financial expenses paid	(175,642,071)	(48,891,937)
Dividend paid	(7,753,028)	(7,768,697)
<b>Net Cash Received/(Used) from Financing Activities</b>	<b>443,613,970</b>	<b>300,580,871</b>
<b>Net Increase /(Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(50,501,164)</b>	<b>4,087,285</b>
Cash & Cash Equivalents at the beginning of the period	147,730,453	130,107,384
Cash & Cash Equivalents at the end of the period	<b>97,229,289</b>	<b>134,194,669</b>
<b>Number of Shares Used to Compute NOCFPS</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Net Operating Cash Flow Per Share</b>	<b>34.1</b>	<b>4.26</b>
		<b>2.68</b>

Sd-  
Chairman

Sd-  
Managing Director

Sd-  
Director

Sd-  
Chief Financial Officer

Sd-  
Company Secretary



**ORION PHARMA LIMITED**  
**Condensed Statement of Cash Flows ( Unaudited)**  
**For Six Month Period Ended 31 December 2024**

Particulars	Amount In BDT	
	July 2024 to December 2024	July 2023 to December 2023
<b>A. Cash Flows from Operating Activities :</b>		
Cash Received from Customers	1,781,076,166	1,931,273,958
Cash paid to Suppliers	(582,350,630)	(725,796,818)
Cash Payment for Operating Expenses	(422,706,568)	(652,623,718)
<b>Cash Generated from Operation</b>	<b>776,018,968</b>	<b>552,853,422</b>
Income Taxes Paid	(28,090,238)	(120,185,674)
<b>Net Cash Generated/(Used) from Operating Activities</b>	<b>747,928,730</b>	<b>432,667,747</b>
<b>B. Cash Flows from Investing Activities :</b>		
Acquisition of Property, Plant & Equipment	(60,668,840)	(11,898,637)
Capital Work in Progress	(1,445,326,947)	(1,338,437,925)
Investment in Subsidiaries, Associate, Securities & Others	6,218,032	412,473,979
Interest, Dividend & Other Income	8,297,053	13,785,867
<b>Net Cash Received/(Used) from Investing Activities</b>	<b>(1,491,480,702)</b>	<b>(924,076,716)</b>
<b>C. Cash Flows from Financing Activities :</b>		
Long Term Loan Received/ (Repaid)	821,143,275	(1,776,129,394)
Short Term Loan Received/ (Repaid)	(33,746,992)	2,420,215,395
Lease obligation	17,867,293	(12,936,354)
Dividend paid	(7,753,028)	(7,768,697)
Interest Paid	(100,343,492)	(30,114,862)
<b>Net Cash Received/(Used) from Financing Activities</b>	<b>697,167,055</b>	<b>593,266,089</b>
<b>Net Increase /(Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(46,384,916)</b>	<b>101,857,121</b>
Cash & Cash Equivalents at the beginning of the period	128,341,450	24,827,980
<b>Cash &amp; Cash Equivalents at the end of the period</b>	<b>81,956,534</b>	<b>126,685,101</b>
<b>Number of Shares Used to Compute NOCFPS</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Net Operating Cash Flow Per Share</b>	<b>34a.1 3.20</b>	<b>1.85</b>

Sd-  
Chairman

Sd-  
Managing Director

Sd-  
Director

Sd-  
Chief Financial Officer

Sd-  
Company Secretary

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Selected Explanatory Notes to the Condensed Consolidated Financial Statements**  
**For Six Month Period Ended 31 December 2024 (Half Yearly)**

**1 Reporting Entity**

**1.1 Background of the Entity**

Orion Pharma Limited earlier called Orion Laboratories Limited was incorporated in 1965 as a private limited company. The Company was converted into a public limited company on 24 July 2010. The registered office of the company is at 153-154 Tejgaon I/A Dhaka-1208 Bangladesh.

The Company is listed both with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE) on 20 March 2013.

**1.2 Nature of Business**

Orion Pharma Limited is engaged in the creation and discovery development manufacturing and marketing of pharmaceutical products including vaccines and health-related consumer products.

**1.3 Subsidiary Companies**

**1.3.1 Orion Power Meghnaghat Limited**

Orion Power Meghnaghat Ltd. was incorporated on 30 June 2010 as a public limited company under the Companies Act 1994 with authorized share capital of Tk. 4000000000 divided into 400000000 Ordinary shares of Tk. 10 each. The company implemented a 100 MW HFO Power based Plant on quick rental basis in Meghnaghat Dhaka to supply electricity to national grid with machineries and equipment supplied by Wartsila OY Finland. Orion Pharma Ltd. holds 95% of equity share of this company directly.

The company has set up a 100 MW HFO Power Plant on quick rental basis in Meghnaghat Sonargaon Narayanganj with machineries and equipment's supplied by Wartsila Finland OY for generation and supply of electricity. The company has signed the contract with Bangladesh Power Development Board (hereinafter referred as BPDB) acting as an off taker to supply power to them solely under the contract No. 09755 executed on June 30 2010. According to the said contract the Government will purchase the power for a period of five (5) years commencing from May 08 2011. The contract has been extended for further five (5) years effective from May 09 2016 vide memo no- 27.00.0000.071.14.035.2013.535 dated 01 December 2016. The contract then expired on 07 May 2021. The government renewed the contract for two (2) years effective from 24 March 2022 vide memo no - 27.11.0000.101.14.020.22-1697 dated: 10 April 2022. The purpose of this contract is to supply of Net Energy Output under the terms and conditions provided "No Electricity No Payment and also without any guaranteed Minimum Off-take" basis by Rental Power Company by BPDB which expired on 23 March 2024. As per memo No.: 27.11.0000.101.14.020.24-1099 dated: 29 April 2024 the company was instructed to resume and continue operation.

**1.3.2 Dutch Bangla Power & Associates Limited**

Dutch Bangla Power & Associates Ltd. was incorporated on 1 July 2010 as a public limited company under the Companies Act 1994 with authorized share capital of Tk. 1000000000 divided into 100000000 ordinary shares of Tk. 10 each. The Company was awarded by the Government of Bangladesh and BPDB to implement 100 MW HFO Power Plant on quick rental basis in Siddhirganj Narayanganj to supply electricity to national grid with machineries and equipment supplied by Wartsila OY Finland. Orion Pharma Ltd. holds 67% of equity share of this Company.

The company has set up a 100 MW HFO Power Plant on quick rental basis in Siddhirganj Narayanganj with machineries and equipments supplied by Wartsila Finland OY for generation and supply of electricity. The company has signed the contract with Bangladesh Power Development Board (hereinafter referred as BPDB) acting as an off taker to supply power to them solely under the contract No. 09756 executed on July 01 2010. According to the said contract the Government will purchase the power for a period of five (5) years commencing from July 21 2011. The contract has been extended for further five (5) years effective from 22 July 2016 vide memo no- 27.00.0000.071.14.122.2010.534 dated 01 December 2016. The contract then expired on 22 July 2021. The government renewed the contract for two (2) years effective from 24 March 2024 vide memo no - 27.11.0000.101.14.020.22-1696 dated: 10 April 2024. The purpose of this contract is to supply of Net Energy Output under the terms and conditions provided "No Electricity No Payment and also without any guaranteed Minimum Off-take" basis by Rental Power Company by BPDB which expired on 23 March 2024. As per memo No.: 27.11.0000.101.14.020.24-1100 dated: 29 April 2024 the company was instructed to resume and continue operation.

#### **1.4 Associate Company Orion Infusion Limited**

Orion Infusion Limited is a public limited company incorporated in Bangladesh on May 05 1983 and is now operating under the banner of Orion Group. Other shareholders of the company are sponsor shareholders foreign investors financial institutions and general public.

The Company was listed with Dhaka Stock Exchange Limited (DSE) on 05 October 1994 and Chittagong Stock Exchange Limited (CSE) on 22 September 1996. Orion Pharma Ltd. holds 21.76 % of equity share of this company directly.

## **2 Basis of Preparation**

### **2.1 Statement of Compliance**

These Condensed Interim Financial Statements of the company comprised the company's and its subsidiaries (together referred to as the 'Group' and individually as 'Group entities') and the Group's interest in associates have been prepared in accordance with International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) in particular International Accounting Standard (IAS) 34: Interim Financial Reporting the Companies Act 1994 Securities and Exchange Rules 1987 and other applicable laws and regulations.

### **2.2 Components of the Condensed Financial Statements**

According to IAS-34 'Interim Financial Reporting' these interim financial statements include the following components-

- i. Condensed Consolidated Statement of Financial Position
- ii. Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
- iii. Condensed Consolidated Statement of Changes in Equity
- iv. Condensed Consolidated Statement of Cash Flows
- v. Selected Explanatory Notes to the Condensed Consolidated Financial Statements

### **2.3 Basis of Measurement**

The financial statements have been prepared on historical cost basis except for certain assets which are stated either at revalued amount or fair market value.

### **2.4 Functional and Presentation Currency**

The financial statements are prepared and presented in Bangladesh Taka (Taka/Tk./BDT) which is the company's functional and presentation currency. All amounts have been rounded off to the nearest integer.

### **2.5 Reporting Period**

These Condensed Interim Financial Statements of the company cover six month period from 1 July 2024 to 31 December 2024.

### **2.6 Date of Authorization**

The financial statements were authorized for issue by the Board of Directors in its meeting held on 29 January 2025 for publication.

### **2.7 Events after the reporting period**

#### **Information regarding subsidiary companies**

For this quarter there was no such issue.

### 3 Accounting Policies and Methods of Computations

The accounting policies and methods of computations followed in preparing these financial statements are same as those used in the annual financial statements prepared and published for the year ended 30 June 2024.

### 4 Subsequent Events

No material events occurred after the reporting date non-disclosure of which could affect the ability of the users of the financial statements to make proper evaluation and decision.

### 5 Acquisition of Property Plant & Equipments of Orion Pharma Ltd. and its subsidiaries during the Period.

*Discloser as per BSEC Notification No. BSEC/CMRRCD/2006-158/208/Admin/81 Dated: 20 June 2018.*

SL No.	Particulars	Amount in BDT	
		31-Dec-24	31-Dec-23
i	Factory & Office Building	28,419,690	52,800
ii	Plant & Machinery	3,893,033	5,508,580
iii	Furniture & Fixtures	3,000	37,270
iv	Office Equipment	1,385,546	2,711,693
v	Vehicle	-	1,953,500
vi	Road & Road Development	-	1,634,794
	<b>Total</b>	<b>33,701,269</b>	<b>11,898,637</b>

SL No.	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24
<b>6.</b>	<b>Property plant and equipment</b>		
	Opening balance	21,077,115,349	13,317,799,927
	Add: Addition during the period	33,701,269	19,594,222
	Transfer from Capital work in Progress	-	8,310,620,491
	Less: Sale /disposal during the period	-	(57,677)
		<b>21,110,816,618</b>	<b>21,647,956,963</b>
	Less: Depreciation charged during the period	(327,715,739)	(570,841,614)
	<b>Written down value</b>	<b>20,783,100,880</b>	<b>21,077,115,349</b>
<b>6a.</b>	<b>Property plant and equipment</b>		
	Opening balance	15,265,180,705	7,228,006,743
	Add: Addition during the period	33,701,269	19,442,622
	Transfer from Capital work in Progress	-	8,310,620,491
	Less: Sale /disposal during the period	-	(57,677)
		<b>15,298,881,974</b>	<b>15,558,012,179</b>
	Less: Depreciation charged during the period	(279,463,196)	(292,831,474)
	<b>Written down value</b>	<b>15,019,418,778</b>	<b>15,265,180,705</b>
<b>7.</b>	<b>Right of use assets</b>		
	Opening Balance	143,942,706	143,366,149
	Add: Addition during the period	26,967,571	4,772,731
		<b>170,910,277</b>	<b>148,138,880</b>
	Less: Disposal/ adjustment	-	(4,196,174)
		<b>170,910,277</b>	<b>143,942,706</b>
	Amortization		
	Opening balance	119,580,834	101,726,647
	Addition during the period	8,600,320	17,854,187
		<b>128,181,154</b>	<b>119,580,834</b>
	<b>Written down value</b>	<b>42,729,124</b>	<b>24,361,873</b>
<b>8.</b>	<b>Capital Work in Progress</b>		
	Opening balance	7,163,967,741	13,064,566,507
	Add: Addition during the period	1,445,326,947	2,410,021,725
	Transfer to Property plant and equipment	-	(8,310,620,491)

SL No.	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24
		<b>8,609,294,688</b>	<b>7,163,967,741</b>

#### 9. Investment in subsidiaries

Name of the subsidiary company	Number of shares	Share holding (%)	Amount in BDT	
			31-Dec-24	30-Jun-24
Orion Power Meghnaghat Ltd.	95,000,000	95.00	950,000,000	950,000,000
Dutch Bangla Power & Associates Ltd.	6,700,000	67.00	67,000,000	67,000,000
<b>Total</b>			<b>1,017,000,000</b>	<b>1,017,000,000</b>

Investment in subsidiaries are stated at cost.

#### 10. Investment in associate

##### Orion Infusion Limited

Opening balance	2,128,615,000	1,490,695,000
Add: Share of profit during the period	4,562,900	9,214,400
Less: Dividend during the period	(5,316,000)	(4,430,000)
Add: Share of other comprehensive income	169,263	36,999
Add: Fair value adjustment	(237,750,163)	633,098,601
	<b>1,890,281,000</b>	<b>2,128,615,000</b>

#### 11. Other investment

Investment in marketable securities (Note 11.1)	12,749,084	16,323,013
Investment in non-Quoted Shares (Note 11.2)	5,921,740,676	5,921,740,676
	<b>5,934,489,760</b>	<b>5,938,063,689</b>

##### 11.1 Investment in marketable securities

AB Investment Limited.	2,406,624	4,248,056
Bank Asia Securities Limited.	3,980,511	4,905,132
LankaBangla Securities Ltd.	6,361,949	7,169,825
	<b>12,749,084</b>	<b>16,323,013</b>

##### 11.2 Investment in non-quoted shares

Orion Power Khulna Limited.	500,000	500,000
Orion Power Dhaka Limited.	500,000	500,000
ICB Islami Bank Limited	246,000	246,000
Orion Infrastructure Limited.	2,117,209,676	2,117,209,676
Energon Renewable (BD) Ltd.	1,500,000	1,500,000
Orion Power Unit - 2 Dhaka Ltd.	3,801,785,000	3,801,785,000
	<b>5,921,740,676</b>	<b>5,921,740,676</b>

##### 11a Other investment

Investment in marketable securities (Note 11a.1)	12,749,084	16,323,013
Investment in non-Quoted Shares (Note 11a.2)	2,120,240,676	2,120,240,676
	<b>2,132,989,760</b>	<b>2,136,563,689</b>

##### 11a.1 Investment in marketable securities

AB Investment Limited.	2,406,624	4,248,056
Bank Asia Securities Limited.	3,980,511	4,905,132
LankaBangla Securities Ltd.	6,361,949	7,169,825
	<b>12,749,084</b>	<b>16,323,013</b>

##### 11a.2 Investment in non-quoted shares

Orion Power Khulna Limited.	500,000	500,000
Orion Power Dhaka Limited.	500,000	500,000
ICB Islami Bank Limited	246,000	246,000
Orion Infrastructure Limited.	2,117,209,676	2,117,209,676
Orion Power Unit - 2 Dhaka Ltd.	1,785,000	1,785,000
	<b>2,120,240,676</b>	<b>2,120,240,676</b>

SL No.	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24
<b>12. Inventories</b>			
Raw materials		194,305,368	223,558,583
Packing materials		82,964,522	112,835,551
Work-in-process		55,819,098	33,940,589
Finished goods		136,314,988	152,492,482
Printing Stationeries		10,556,536	16,169,876
Promotional materials		20,255,400	26,715,542
Material in transit		104,323,538	71,926,478
Spare parts		511,872,063	483,494,642
Inventory HFO & LFO		455,775,812	578,189,186
		<b>1,572,187,325</b>	<b>1,699,322,929</b>

**12.a Inventories**

Raw materials		194,305,368	223,558,583
Packing materials		82,964,522	112,835,551
Work-in-process		55,819,098	33,940,589
Finished goods		136,314,988	152,492,482
Printing Stationeries		10,556,536	16,169,876
Promotional materials		20,255,400	26,715,542
Material in transit		104,323,538	71,926,478
		<b>604,539,450</b>	<b>637,639,101</b>

**13. Trade & other receivables**

Trade receivables		4,384,088,523	4,210,077,730
Other receivables (Note-13.1)		10,061,821,260	9,705,636,284
		<b>14,445,909,783</b>	<b>13,915,714,014</b>

Trade receivables are unsecured considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

**Ageing of the above balance is as follows:**

Below 180 days		4,384,088,523	4,210,077,730
Above 180 days		-	-
		<b>4,384,088,523</b>	<b>4,210,077,730</b>

SL. No.	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24
I	Trade receivables considered good in respect of which the company is fully secured	4,384,088,523	4,210,077,730
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security	-	-
III	Trade receivables considered doubtful or bad	-	-
IV	Trade receivables due by any director or other officer of the company	-	-
V	Trade receivables due by common management	-	-
VI	The maximum amount of receivable due by any director or other officer of the company	-	-
	<b>Total</b>	<b>4,384,088,523</b>	<b>4,210,077,730</b>

**13.1 Other receivables**

Claim receivables insurance & others		4,384,176	4,352,154
Dividend receivable		5,316,000	4,430,000
Interest on FDR		712,503	578,164
Other receivables		1,221,152,230	1,220,885,230
Current account with other related companies (Note. 13.1.1)		8,830,256,351	8,475,390,736
		<b>10,061,821,260</b>	<b>9,705,636,284</b>

SL No.	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24
<b>13.1.1 Current account with other related companies</b>			
	Noakhali Gold Food Ltd.	10,859,928	10,859,928
	Orion Properties Ltd.	23,550,142	23,550,142
	Orion Gas Limited	90,916,636	90,911,272
	Orion Power Khulna Ltd.	1,076,950,154	1,084,624,104
	Orion Power Dhaka Ltd.	2,370,355,084	2,370,263,896
	Jafflong Tea Company Ltd.	70,894,479	73,302,850
	Orion Agro Product Ltd.	273,891,022	275,775,350
	Interior Accom Consortium Ltd.	85,407,892	85,407,892
	Digital Power & Associate Ltd.	1,222,742,774	1,045,385,127
	Orion Footwear Ltd.	258,954,807	258,954,807
	Panbo Bangla Mashroom Ltd.	38,128,200	38,128,200
	Orion Power Unit 2 Dhaka Ltd.	952,316,764	952,331,473
	Orion Home Appliance Ltd.	139,697,496	139,697,496
	Orion Hospitals Ltd.	26,222,300	26,222,300
	Orion Power Rupsha Ltd.	122,429,699	122,929,699
	Energion Renewable (BD) Ltd.	683,407,792	683,407,792
	Orion Quaderia Textiles Ltd.	187,910,000	187,910,000
	Orion Tea Company Ltd	381,766,239	379,357,868
	SAZKA Natural Care Ltd.	108,663,500	108,663,500
	Orion Power Sonargaon Ltd	655,609,444	496,125,040
	Orion Knit Textiles Ltd.	21,582,000	21,582,000
	Orion Infrastructure Limited	28,000,000	-
		<b>8,830,256,351</b>	<b>8,475,390,736</b>

**13.a Trade & other receivables**

	Trade receivables	280,608,407	372,318,481
	Other receivables (Note - 13a.1)	8,566,250,094	8,572,361,001
		<b>8,846,858,502</b>	<b>8,944,679,482</b>

Trade receivables are unsecured considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

**Ageing of the above balance is as follows:**

	Below 180 days	280,608,407	372,318,481
	Above 180 days	-	-
		<b>280,608,407</b>	<b>372,318,481</b>

SL No	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24
I	Trade receivables considered good in respect of which the company is fully	280,608,407	372,318,481
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security		-
III	Trade receivables considered doubtful or bad		-
IV	Trade receivables due by any director or other officer of the company		-
V	Trade receivables due by common management		-
VI	The maximum amount of receivable due by any director or other officer of the		-
	<b>Total</b>	<b>280,608,407</b>	<b>372,318,481</b>

SL No.	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24
<b>13a.1</b>	<b>Other receivables</b>		
	Claim receivables insurance & others	4,384,176	4,352,154
	Dividend receivable	5,316,000	4,430,000
	Interest on FDR	712,503	578,164
	Other receivables	938,766,019	938,766,019
	Current account with subsidiaries (13a.1.1)	346,805,959	346,395,908
	Current account with other related companies (13a.1.2)	7,270,265,437	7,277,838,756
		<b>8,566,250,094</b>	<b>8,572,361,001</b>
<b>13a.1.1</b>	<b>Current account with subsidiaries</b>		
	Dutch Bangla Power & Associates Limited.	346,805,959	346,395,908
		<b>346,805,959</b>	<b>346,395,908</b>
<b>13a.1.2</b>	<b>Current account with other related companies</b>		
	Orion Properties Ltd.	21,780,585	21,780,585
	Orion Power Khulna Ltd.	1,076,950,154	1,084,624,104
	Orion Power Dhaka Ltd.	2,284,334,998	2,284,243,810
	Interior Accom Consortium Ltd.	118,564,892	118,564,892
	Orion Agro Product Ltd.	267,922,512	267,922,512
	Orion Power Unit -2 Dhaka Ltd.	1,062,254,582	1,062,250,503
	Digital Power & Associates Ltd.	196,111,884	196,111,884
	Orion Hospitals Ltd.	21,222,300	21,222,300
	Energon Renewables (BD) Ltd.	698,707,792	698,707,792
	Orion Home Appliances Ltd.	131,890,000	131,890,000
	SAZKA Natural Care Ltd.	108,663,500	108,663,500
	Orion Gas Ltd.	41,716,636	41,711,272
	Panbo Bangla Mushroom Ltd	38,128,200	38,128,200
	Orion Footwear Ltd.	120,292,645	120,292,645
	Orion Tea Company Ltd	379,357,868	379,357,868
	Orion Power Sonargaon Ltd	501,980,411	501,980,411
	Jafflong Tea Company Ltd.	70,894,479	70,894,479
	Orion Knit Textiles Ltd.	21,582,000	21,582,000
	Orion Quaderia Textiles Ltd	107,910,000	107,910,000
		<b>7,270,265,437</b>	<b>7,277,838,756</b>



SL No.	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24
<b>14. Advances deposits and prepayments</b>			
<b>Advances:</b>			
Advance income tax (Note-14.1)	321,205,697	295,975,607	
Advance imprest money	165,500	123,500	
Advance motor cycle	5,241,060	6,437,957	
Advance - car loan	284,808	433,522	
Collection advance	13,567,358	11,097,734	
Advance to C&F agents	254,586	6,662,649	
Advance office rent	3,189,626	2,822,634	
Advance against land purchase	97,260,635	97,260,635	
Advance to employee	7,882,674	8,129,682	
Other advance	94,206	1,190,687	
Advance Cash Purchase	523,640	852,328	
Advance to Supplier	149,292,642	173,158,820	
Machinery in Transit	23,740,146	185,425,315	
	<b>622,702,577</b>	<b>789,571,070</b>	
<b>Deposits:</b>			
Earnest money	9,833,415	9,808,415	
Security deposit	43,224,333	48,059,193	
Bank guarantee	58,530,166	58,477,623	
Lease deposit	-	254,133	
L/C Margin & Balance	127,972,434	127,972,434	
	<b>239,560,349</b>	<b>244,571,798</b>	
<b>Prepayments:</b>			
Insurance premium	465,342	110,830	
Bank gurantteecommission & charge	425,752	10,543,237	
	<b>891,094</b>	<b>10,654,068</b>	
	<b>863,154,020</b>	<b>1,044,796,936</b>	
<b>14.1 Advance income tax</b>			
Opening balance	295,975,607	253,914,819	
Add: Addition during the period	25,230,090	42,060,789	
Closing balance	<b>321,205,697</b>	<b>295,975,607</b>	
<b>14.a Advances deposits &amp; prepayments</b>			
<b>Advances:</b>			
Advance income tax (Note -14a.1)	318,502,753	293,412,515	
Advance imprest money	165,500	123,500	
Motor cycle advance	5,241,060	6,437,957	
Advance - car loan	284,808	433,522	
Collection advance	13,567,358	11,097,734	
Advance to C&F agents	254,586	6,662,649	
Advance office rent	3,189,626	2,822,634	
Advance against land purchase	97,260,635	97,260,635	
Advance to Employee	7,074,599	7,808,198	
Others Advance	94,206	1,190,687	
Advance Cash Purchase	523,640	852,328	
Advance Paid to Suppliers	123,967,217	156,947,314	
Machinery in Transit	23,740,146	185,425,315	
	<b>593,866,133</b>	<b>770,474,987</b>	
<b>Deposits</b>			
Earnest money	9,833,415	9,808,415	
Security deposit	43,224,333	48,059,193	
Bank guarantee	3,715,790	3,663,247	
Lease deposit	-	254,133	
L/C Margin & Balance	127,700,000	127,700,000	
	<b>184,473,538</b>	<b>189,484,988</b>	
	<b>778,339,671</b>	<b>959,959,975</b>	

SL No.	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24
<b>14a.1</b>	<b>Advance income tax</b>		
	Opening balance	293,412,515	251,801,807
	Addition during the period	25,090,238	41,610,707
	<b>Closing balance</b>	<b>318,502,753</b>	<b>293,412,515</b>
<b>15.</b>	<b>Fixed deposit with banks</b>		
	Social Islami Bank Limited. Principal Branch Dhaka.	10,832,135	10,473,026
	Agrani Bank Ltd.	40,197,078	35,347,312
		<b>51,029,213</b>	<b>45,820,338</b>
<b>16.</b>	<b>Cash &amp; cash equivalents</b>		
	Cash in hand (Note -16.1)	10,307,754	5,608,660
	Cash at B/O account (Note -16.2)	65,522	66,872
		<b>10,373,276</b>	<b>5,675,532</b>
	<b>Balance with banks on account</b>		
	Current account	64,830,807	133,925,252
	Short term deposit account	22,025,207	8,129,669
		<b>86,856,014</b>	<b>142,054,920</b>
		<b>97,229,289</b>	<b>147,730,452</b>
<b>16.1</b>	<b>Cash in hand</b>		
	Head office	3,036,330	2,400,048
	Depot office	7,271,424	3,208,613
		<b>10,307,754</b>	<b>5,608,660</b>
<b>16.2</b>	<b>Cash at B/O account</b>		
	Bank Asia Securities Limited.	19,549	19,999
	Jahan Securities Limited.	624	1,074
	LankaBangla Securities Ltd.	42,249	42,699
	Shanta Securities Ltd.	3,100	3,100
		<b>65,522</b>	<b>66,872</b>
<b>16.a</b>	<b>Cash and cash equivalents</b>		
	Cash in hand (Note -16a.1)	6,907,962	3,394,262
	Cash at B/O account (Note -16a.2)	62,422	63,772
		<b>6,970,384</b>	<b>3,458,034</b>
	<b>Cash at Bank:</b>		
	Current account	52,960,943	116,753,748
	Short term deposit account	22,025,207	8,129,669
		<b>74,986,150</b>	<b>124,883,416</b>
		<b>81,956,534</b>	<b>128,341,450</b>
<b>16a.1</b>	<b>Cash in hand</b>		
	Head office - central cash & main cash	1,671,737	1,414,262
	Depot office - petty cash	5,236,225	1,980,000
		<b>6,907,962</b>	<b>3,394,262</b>
<b>16a.2</b>	<b>Cash at B/O account</b>		
	Bank Asia Securities Limited	19,549	19,999
	Jahan Securities Limited	624	1,074
	LankaBangla Securities Ltd.	42,249	42,699
		<b>62,422</b>	<b>63,772</b>

SL No.	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24

**17. Share capital**

**Authorized capital**

500000000 ordinary shares of Tk. 10 each	<b>5,000,000,000</b>	<b>5,000,000,000</b>
--	----------------------	----------------------

**Issued subscribed and paid-up capital**

234000000 ordinary shares of Tk. 10 each	<b>2,340,000,000</b>	<b>2,340,000,000</b>
--	----------------------	----------------------

**Shareholding position of the company**

Range of Shareholding	Number of Shareholders	Number of Shares	% of holding	
			31-Dec-24	30-Jun-24
Up to 500 Shares	25,708	3,760,735	1.61%	1.66%
501 to 5000 Shares	12,492	23,447,162	10.02%	9.49%
5001 to 10000 Shares	2,012	14,843,006	6.34%	5.92%
10001 to 20000 Shares	1,139	16,271,632	6.95%	6.53%
20001 to above	1,055	175,677,465	75.08%	76.40%
<b>Total</b>	<b>42,406</b>	<b>234,000,000</b>	<b>100%</b>	<b>100%</b>

Categories of shareholders	Number of Shareholders	Number of Shares	% of holding	
			31-Dec-24	30-Jun-24
Sponsors	5	74,841,600	31.98%	31.98%
Foreign Investor	199	317,022	0.14%	0.08%
Financial institutions	656	51,198,862	21.88%	21.56%
General public	41,546	107,642,516	46.00%	46.38%
<b>Total</b>	<b>42,406</b>	<b>234,000,000</b>	<b>100%</b>	<b>100%</b>

Orion Power Meghnaghat Limited	Number of Shares	Face Value	% of holding	
			31-Dec-24	30-Jun-24
Orion Pharma Limited	95,000,000	950,000,000	95.00%	95.00%
Integral Energy Limited	3,000,000	30,000,000	3.00%	3.00%
Jafflong Tea Company Limited	500,000	5,000,000	0.50%	0.50%
Mr. Mohammad Obaidul Karim	500,000	5,000,000	0.50%	0.50%
Mr. Salman Obaidul Karim	600,000	6,000,000	0.60%	0.60%
Mrs. Arzuda Karim	350,000	3,500,000	0.35%	0.35%
Haarhuis Generation B.V.	50,000	500,000	0.05%	0.05%
<b>Total</b>	<b>100,000,000</b>	<b>1,000,000,000</b>	<b>100%</b>	<b>100%</b>

Dutch Bangla Power & Associates Limited	Number of Shares	Face Value	% of holding	
			31-Dec-24	30-Jun-24
Orion Pharma Limited	6,700,000	67,000,000	67.00%	67.00%
Shenzhen Nanshan Power Co. Ltd.	50,000	500,000	0.50%	0.50%
Mohammad Obaidul Karim	100,000	1,000,000	1.00%	1.00%
Salman Obaidul Karim	3,087,500	30,875,000	30.88%	30.88%
Orion Tea Company Ltd.	50,000	500,000	0.50%	0.50%
Jafflong Tea Co. Ltd.	2,500	25,000	0.03%	0.03%
Mrs. Arzuda Karim	10,000	100,000	0.10%	0.10%
<b>Total</b>	<b>10,000,000</b>	<b>100,000,000</b>	<b>100%</b>	<b>100%</b>

**18. Reserves**

Fair value gain/(loss) on investment in associate (Note -18.1)	1,796,048,731	2,033,798,895
Fair value gain /(loss) on marketable securities (Note -18.2)	(14,822,714)	(11,606,178)
Share of other comprehensive income of associate (Note - 18.3)	6,944,137	6,774,874
Revaluation surplus on property plant and equipment (Note -18.4)	1,650,596,551	1,654,377,559
	<b>3,438,766,706</b>	<b>3,683,345,150</b>

SL No.	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24
<b>18.1</b>	<b>Fair value gain on investment in associate</b>		
	Opening balance	2,033,798,895	1,400,700,294
	Fair value gain/ (loss) during the period	(237,750,163)	633,098,601
		<b>1,796,048,731</b>	<b>2,033,798,895</b>
<b>18.2</b>	<b>Fair value gain/(loss) on marketable securities</b>		
	Opening balance	(11,606,178)	(7,704,833)
	Adjustment of sale of marketable securities	1,350	2,860,258
	Fair value gain/(loss) on marketable securities (Note - 18.2.1)	(3,575,279)	(7,195,085)
	Transferred to deferred tax assets/(liabilities)	357,393	433,483
		<b>(14,822,714)</b>	<b>(11,606,178)</b>
<b>18.2.1</b>	<b>Fair value gain/(loss) on marketable securities during the period</b>		
	Unrealized gain/(loss) position (closing)	(16,469,682)	(12,895,753)
	Unrealized gain/(loss) position (opening)	(12,895,753)	(8,560,925)
	<b>Total change during the period</b>	<b>(3,573,929)</b>	<b>(4,334,828)</b>
	Fair value adjustment for sale of securities (realized loss)	(1,350)	(2,860,258)
	<b>Unrealized gain/(loss) during the period</b>	<b>(3,575,279)</b>	<b>(7,195,085)</b>
<b>18.3</b>	<b>Share of other comprehensive income</b>		
	Opening balance	6,774,874	6,737,875
	Add: Addition during the period	169,263	36,999
		<b>6,944,137</b>	<b>6,774,874</b>
<b>18.4</b>	<b>Revaluation surplus on property plant &amp; equipment</b>		
	Opening balance	1,654,377,559	1,667,479,327
	Adjustment during the period to retained earnings for depreciation	(4,203,441)	(14,040,509)
	Adjustment of deferred tax on revaluation surplus	422,433	938,741
		<b>1,650,596,551</b>	<b>1,654,377,559</b>
<b>18.a</b>	<b>Reserve</b>		
	Fair value gain on investment in associates (Note - 18a.1)	1,796,048,731	2,033,798,894
	Fair value gain/(loss) on marketable securities (Note - 18a.2)	(14,822,713)	(11,606,177)
	Share of other comprehensive income (Note - 18a.3)	6,944,138	6,774,874
	Revaluation surplus on property plant & equipment (Note - 18a.4)	1,302,486,966	1,304,880,755
		<b>3,090,657,122</b>	<b>3,333,848,346</b>
<b>18a.1</b>	<b>Fair value gain on investment in associates</b>		
	Opening balance	2,033,798,894	1,400,700,294
	Fair value gain/(loss) during the period	(237,750,163)	633,098,601
		<b>1,796,048,731</b>	<b>2,033,798,894</b>
<b>18a.2</b>	<b>Fair value gain/(loss) on marketable securities</b>		
	Opening balance	(11,606,177)	(7,704,832)
	Adjustment for marketable securities	1,350	2,860,258
	Fair value gain/(loss) on marketable securities D/Y (Note - 18a.2.1)	(3,575,279)	(7,195,085)
	Transferred to deferred tax assets/(liabilities)	357,393	433,483
		<b>(14,822,713)</b>	<b>(11,606,177)</b>

SL No.	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24
<b>18a.2.1 Fair value gain/(loss) on marketable securities during the period</b>			
	Unrealized gain/(loss) position (closing)	(16,469,682)	(12,895,753)
	Unrealized gain/(loss) position (opening)	(12,895,753)	(8,560,925)
	Fair value adjustment for sale of securities realized	(1,350)	(2,860,258)
	<b>Unrealized gain/(loss) during the period</b>	<b>(3,575,279)</b>	<b>(7,195,085)</b>
<b>18a.3 Share of other comprehensive income</b>			
	Opening balance	6,774,874	6,737,875
	Add: Addition during the period	169,263	36,999
		<b>6,944,138</b>	<b>6,774,874</b>
<b>18a.4 Revaluation surplus on property plant &amp; equipment</b>			
	Opening balance	1,304,880,755	1,310,200,284
	Adjustment during the period to retained earnings for depreciation	(2,816,222)	(6,258,270)
	Adjustment of deferred tax on revaluation surplus	422,433	938,741
		<b>1,302,486,966</b>	<b>1,304,880,755</b>
<b>19. Retained earnings</b>			
	Opening balance	7,499,339,162	7,400,327,363
	Net profit after tax	(47,195,730)	318,117,433
	Dividend for the period	(234,000,000)	(234,000,000)
	Adjustment for depreciation on revaluation surplus	4,203,441	14,040,509
	Adjustment for Right of use Assets	-	853,857
		<b>7,222,346,873</b>	<b>7,499,339,162</b>
<b>19.a Retained Earnings</b>			
	Opening balance	961,565,844	973,857,096
	Net profit after tax	51,875,592	214,596,621
	Dividend for the period	(234,000,000)	(234,000,000)
	Adjustment for depreciation on revaluation surplus	2,816,222	6,258,270
	Adjustment for Right of use Assets	-	853,857
		<b>782,257,658</b>	<b>961,565,844</b>
<b>20. Non-controlling interest</b>			
	Opening balance	1,543,272,725	1,509,624,870
	Share of operating profit	(38,630,093)	33,647,855
	Closing balance	<b>1,504,642,633</b>	<b>1,543,272,725</b>
<b>21 Syndicated loan and other long term loans</b>			
	Agrani Bank Ltd. -BMRE	4,983,992,171	4,737,011,986
	Social Islami Bank Ltd	1,476,621,645	1,425,931,955
	Term Loan -SBLC Agrani Bank Ltd	3,540,000,000	3,540,000,000
	Term Loan Capital Machinery - UPAS L/C	-	37,996,000
	AL-Arafa Islami Bank Ltd.	2,322,395,458	2,217,169,601
	ODDO BHF AG Finance	67,349,871	67,349,871
	Rupali Bank Ltd.	2,975,252,999	2,786,902,839
	Janata Bank Ltd	4,934,551,143	4,598,670,931
	Agrani Bank Ltd.	2,452,050,677	2,520,037,506
		<b>22,752,213,963</b>	<b>21,931,070,689</b>
	Less: Current portion of long term loan (Note 21.1)	(67,349,871)	(67,349,871)
		<b>22,684,864,092</b>	<b>21,863,720,817</b>
<b>21.1 Current portion of long term loan</b>			
	ODDO BHF AG Finance	67,349,871	67,349,871
		<b>67,349,871</b>	<b>67,349,871</b>

SL No.	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24

### 21.a Long term loan

Agrani Bank Ltd. -BMRE	4,983,992,171	4,737,011,986
Social Islami Bank Ltd.	1,476,621,645	1,425,931,955
Term Loan -SBLC Agrani Bank Ltd.	3,540,000,000	3,540,000,000
Term Loan Capital Machinery - UPAS L/C	-	37,996,000
AL-Arafa Islami Bank Ltd.	2,322,395,458	2,217,169,601
ODDO BHF AG Finance	67,349,871	67,349,871
Rupali Bank Ltd.	2,975,252,999	2,786,902,839
Janata Bank Ltd	4,934,551,143	4,598,670,931
Agrani Bank Ltd.	2,452,050,677	2,520,037,506
	<b>22,752,213,963</b>	<b>21,931,070,689</b>
Less: Current portion of long term loan (Note 21.a.1)	(67,349,871)	(67,349,871)
	<b>22,684,864,092</b>	<b>21,863,720,817</b>

#### 21.a.1 Current portion long term loan

ODDO BHF AG Finance	67,349,871	67,349,871
	<b>67,349,871</b>	<b>67,349,871</b>

### 22 Lease obligation

Phoenix Finance & Investment Ltd.	-	272,122
Lease obligation (Office rent)	45,525,312	27,385,897
	<b>45,525,312</b>	<b>27,658,019</b>
Current portion of lease obligation (22.1)	(15,407,808)	(13,943,551)
	<b>30,117,504</b>	<b>13,714,468</b>

#### 22.1 Current portion of lease obligation

Phoenix Finance & Investment Ltd.	-	272,122
Lease obligation (Office rent)	15,407,808	13,671,429
	<b>15,407,808</b>	<b>13,943,551</b>

### 23 Deferred tax liability

Opening balance	315,432,155	157,696,141
Adjustment for deferred tax expenses /(income) (Note-23.1)	44,745,051	159,108,238
Adjustment for deferred tax on revaluation surplus (Note-23.2)	(779,826)	(1,372,223)
	<b>359,397,380</b>	<b>315,432,156</b>

#### 23.1 Adjustment during the year on deferred tax on PPE

Deferred tax liability on PPE (closing)	314,056,255	269,311,204
Deferred tax liability on PPE (opening)	269,311,204	110,202,966
<b>Deferred tax expenses/(income)</b>	<b>44,745,051</b>	<b>159,108,238</b>

Particular	WDV as on 31 December 2024		Amount in BDT	
	Tax Base	Accounting Base	Deferred Tax Liability as on 31 December 2024	Deferred Tax Liability as on 30 June 2024
Written down value of property plant and equipment	9,432,484,053	10,828,289,632	(314,056,255)	(269,311,204)

#### 23.2 Adjustment of deferred tax on revaluation Surplus

Deferred tax liability on revaluation surplus (Closing) (Note-23.2.1)	45,341,125	46,120,951
Deferred tax liability on revaluation surplus (Opening)	46,120,951	47,493,175

SL No.	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24
	Deferred tax expenses/(income)	(779,826)	(1,372,223)

### 23.2.1 Adjustment of deferred tax on revaluation surplus

Particulars	WDV as on 31 December 2024		Amount in BDT	
	Tax Base	Accounting Base	Deferred Tax Liability as on 31 December 2024	Deferred Tax Liability as on 30 June 2024
Revaluation reserved on land & land development	-	1,298,728,729	(38,961,862)	(38,961,862)
Revaluation reserved factory & office building	-	42,186,174	(6,327,926)	(6,660,975)
Revaluation reserved plant & machinery	-	11,322,036	(1,698,305)	(1,787,690)
Revaluation reserve on marketable securities	-	(16,469,682)	1,646,968	1,289,575
<b>Total</b>	<b>-</b>	<b>1,335,767,257</b>	<b>(45,341,125)</b>	<b>(46,120,951)</b>

### 24. Short term loans

Cash credit (Hypo) Agrani Bank Ltd.	330,626,809	359,821,487
LTR Agrani Bank Ltd.WASA Corporate Branch	138,681,655	143,233,969
Loan against marketable securities	53,121,664	53,121,664
	<b>522,430,128</b>	<b>556,177,120</b>

### 25 Trade and other payables

Goods suppliers & manufacturer	5,646,985,943	5,096,894,653
Other payable	311,532,913	327,752,169
Current account with inter companies (Note -25.1)	1,090,624,881	1,039,045,934
	<b>7,049,143,737</b>	<b>6,463,692,757</b>

### 25.1 Current account with inter companies

Orion Capital Ltd.	18,420,000	18,420,000
Orion Oil & Shipping Ltd.	1,069,204,881	1,017,625,934
Orion Ship Management Ltd.	3,000,000	3,000,000
	<b>1,090,624,881</b>	<b>1,039,045,934</b>

### 25.a Trade and other payables

Goods suppliers & manufacturer	375,044,104	382,449,535
Other payables	40,495,568	67,817,868
	<b>415,539,672</b>	<b>450,267,403</b>

### 26 Employee benefits

Workers welfare fund (Note -26.1)	16,329,229	15,817,871
Bangladesh workers welfare foundation (Note -26.2)	19,458,707	18,947,348
Workers profit participation fund (Note -26.3)	116,560,106	112,469,234
	<b>152,348,043</b>	<b>147,234,452</b>

### 26.1 Workers welfare fund

Opening balance	15,817,871	13,198,802
Add: Addition for the period	511,359	2,619,068
Less: Payment during the period	-	-
	<b>16,329,229</b>	<b>15,817,871</b>

### 26.2 Bangladesh workers welfare foundation

Opening balance	18,947,348	19,897,506
-----------------	------------	------------

SL No.	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24
	Add: Addition for the year	511,359	2,619,068
	Less: Payment during the period	-	(3,569,226)
		<b>19,458,707</b>	<b>18,947,348</b>
<b>26.3</b>	<b>Workers profit participation fund</b>		
	Opening balance	112,469,234	96,300,070
	Add: Addition for the year	4,090,873	20,952,547
	Less: Payment during the period	-	(4,783,384)
		<b>116,560,106</b>	<b>112,469,234</b>
<b>26.a</b>	<b>Employee benefits</b>		
	Workers welfare fund (Note -26.a.1)	5,575,926	5,064,567
	Bangladesh workers welfare foundation (Note -26.a.2)	11,269,577	10,758,218
	Workers profit participation fund (Note -26.a.3)	38,952,228	34,861,355
		<b>55,797,731</b>	<b>50,684,141</b>
<b>26.a.1</b>	<b>Workers welfare fund</b>		
	Opening Balance	5,064,567	3,131,342
	Addition during the period	511,359	1,933,225
	Payment during the period	-	-
		<b>5,575,926</b>	<b>5,064,567</b>
<b>26.a.2</b>	<b>Bangladesh workers welfare foundation</b>		
	Opening balance	10,758,218	10,970,408
	Addition for the period	511,359	1,933,225
	Payment during the period	-	(2,145,415)
		<b>11,269,577</b>	<b>10,758,218</b>
<b>26.a.3</b>	<b>Workers profit participation fund</b>		
	Opening Balance	34,861,355	19,395,555
	Addition during the period	4,090,873	15,465,800
		<b>38,952,228</b>	<b>34,861,355</b>
	WPPF is charged @ 5% of net profit before tax as per labour law Act 2006 (Amended in 2013 ) whereas 80% is allocated to "Workers profit participation fund" 10% to "Employee welfare fund" and 10% to "Bangladesh workers welfare foundation".		
<b>27.</b>	<b>Accrued expenses</b>		
	Salary and wages payable	94,107,553	96,402,075
	Director remuneration payable	19,281,459	11,462,918
	Depot expenses payable	1,131,443	1,813,600
	Telephone & mobile bill payable	4,016,423	4,193,441
	Payable for final settlement of employee	10,975,660	21,598,569
	Utilities payable	9,917,737	11,681,502
	Provision for income tax (Note 27.1)	311,704,167	304,490,093
	Corporate governance audit fees	69,000	69,000
	Statutory Audit fees	-	1,435,000
	Interest payable on Mashreq Dubai	2,548,000	3,618,656
	Retention money	3,618,656	2,548,000
		<b>457,370,098</b>	<b>459,312,854</b>
<b>27.1</b>	<b>Provision for income tax</b>		
	Opening balance	304,490,093	435,261,134
	Add: Addition during the period	10,214,073	22,154,543
		<b>314,704,167</b>	<b>457,415,677</b>
	Less: Payment/AIT adjustment during the period	(3,000,000)	(152,925,584)



SL No.	Particulars	Amount in BDT	
		31-Dec-24	30-Jun-24
		<b>311,704,167</b>	<b>304,490,093</b>

**27.a Accrued expenses**

Salary and wages payable	70,688,678	74,620,291
Director remuneration payable	300,000	300,000
Depot expenses payable	1,131,443	1,813,600
Telephone & mobile bill payable	4,016,423	4,193,441
Payable for final settlement of employee	10,975,660	12,000,037
Utilities payable	9,917,737	11,681,502
Provision for income tax (Note - 26.a.1)	311,704,167	304,490,093
Statutory Audit fees	-	690,000
Corporate governance audit fees	69,000	69,000
	<b>408,803,108</b>	<b>409,857,964</b>

**27.a.1 Provision for income tax**

Opening balance	304,490,093	435,261,134
Add: Addition during the period	10,214,073	22,154,543
	<b>314,704,167</b>	<b>457,415,677</b>
Less: Payment/AIT adjustment during the period	(3,000,000)	(152,925,584)
<b>Closing balance</b>	<b>311,704,167</b>	<b>304,490,093</b>

SL No.	Particulars	Amount in BDT	
		July 2024 to December 2024	July 2023 to December 2023
<b>28. Revenue from net sales</b>			
Local sales		1,568,321,291	1,877,252,393
Export sales		121,044,802	72,347,584
Revenue from power generation (Note-28.1)		817,570,779	3,795,598,747
		<b>2,506,936,871</b>	<b>5,745,198,724</b>
<b>28.1 Revenue from power generation</b>			
Reference energy price (variable - O&M)		137,345,898	649,301,184
HFO received from OOSL & BPDB		680,224,881	3,146,297,563
Foreign exchange gain /(loss)		-	-
		<b>817,570,779</b>	<b>3,795,598,747</b>
<b>28.a Revenue from net sales</b>			
Local sales		1,568,321,291	1,877,252,393
Export sales		121,044,802	72,347,584
		<b>1,689,366,093</b>	<b>1,949,599,977</b>
<b>29 Financial expense</b>			
Agrani Bank Limited, Cash Credit ( Hypo.)		22,286,041	17,564,192
Agrani Bank Limited, LTR		9,207,533	7,121,600
Phoenix Finance & Investments Ltd.		-	2,931,695
Finance cost on lease obligation (Office rent)		1,260,228	1,570,200
Bank Charge ,commission & Fees		10,342,616	15,712,314
Interest on Long Term Borrowing		64,955,963	3,991,937
Social Islamic Bank Ltd.		67,589,690	-
		<b>175,642,071</b>	<b>48,891,937</b>
<b>29a Financial expenses</b>			
Agrani Bank Limited, Cash Credit ( Hypo.)		22,286,041	17,564,192
Agrani Bank Limited, LTR		9,207,533	7,121,600
Phoenix Finance & Investments Ltd.		-	2,931,695
Finance cost on lease obligation (Office rent)		1,260,228	1,570,200
Bank Commision, Fees, VAT and Other Charges		-	927,175
Social Islamic Bank Ltd.		67,589,690	-
		<b>100,343,492</b>	<b>30,114,862</b>
<b>30. Interest &amp; other income</b>			
Interest on FDR		3,444,653	1,431,540
Dividend income		641,435	303,275
Others Income		596,315	3,243,854
Cash Incentive		3,616,000	8,847,400
Gain/(loss) on sale of marketable securities (Note 30.a.1)		(1,350)	(40,203)
		<b>8,297,053</b>	<b>13,785,867</b>
<b>30.a Interest &amp; other income</b>			
Interest on FDR		3,444,653	1,431,540
Dividend income		641,435	303,275
Others Income		596,315	3,243,854
Cash Incentive		3,616,000	8,847,400
Gain/(loss) on sale of marketable securities (Note 33.a.1)		(1,350)	(40,203)
		<b>8,297,053</b>	<b>13,785,867</b>
<b>30a.1 Income on sale of marketable securities</b>			
Gain/(loss) on sale of marketable securities		-	(38,353)
Interest on portfolio credit and others		(1,350)	(1,850)
		<b>(1,350)</b>	<b>(40,203)</b>

SL No.	Particulars	Amount in BDT	
		July 2024 to December 2024	July 2023 to December 2023
<b>31. Current tax</b>			
Profit before tax		102,271,817	267,074,338
Add: Accounting depreciation		288,063,516	140,087,628
Less: Tax depreciation		(457,146,619)	(90,253,410)
Rights og Use Assets		(11,553,647)	-
Taxable income		<b>(78,364,933)</b>	<b>316,908,556</b>

#### Income tax provision

Particulars	Taxable Income	Taxable Amount	
		31-Dec-24	31-Dec-23
Income tax on taxable profit	(86,334,248)	(17,266,850)	67,015,583
Income tax on export net profit	7,327,880	732,788	1,114,970
Cash Incentive	-	-	884,740
Income tax on dividend received	641,435	128,287	60,655
<b>Total</b>	<b>(78,364,933)</b>	<b>(16,405,775)</b>	<b>69,075,948</b>

#### Minimum Tax

##### Calculation of gross receipt

Revenue from net sales	1,689,366,093	1,949,599,977
Interest on FDR	3,444,653	1,431,540
Dividend income	641,435	303,275
Others income	596,315	3,243,854
Gain / (loss) on foreign exchange fluctuations	8,297,053	13,785,867
<b>Total Gross Receipts</b>	<b>1,702,345,549</b>	<b>1,968,364,513</b>
Minimum Tax (0.60% On Total Gross Receipts)	<b>10,214,073</b>	<b>11,810,187</b>
Tax provision whichever is higher	<b>10,214,073</b>	<b>69,075,948</b>

Income tax provision is higher between tax at regular rate on income and minimum tax on gross receipts U/S 163 of ITA 2023. Hence tax at regular rate is accounted for as it is higher than the minimum tax.

#### 32 Earnings per share (EPS)

The computation is given below:

Net profit after tax	(47,195,730)	286,917,721
Ordinary shares outstanding during the period	234,000,000	234,000,000
<b>Earning per share</b>	<b>(0.20)</b>	<b>1.23</b>

Revenue of Orion Pharma Ltd. during the reporting period has decreased compared to the same six-month period in the previous period, due to the country's economic situation. Furthermore, two subsidiary power generation companies have remained idle since September 2024 because no requisition for electricity was received from the Bangladesh Power Development Board (BPDB even though there are no capacity payments, and these power plants have the lowest tariff rates.

#### 32a Earnings per share

The computation is given below:

Net profit after tax	51,875,592	213,816,557
Ordinary shares outstanding during the period	234,000,000	234,000,000
<b>Earnings per share</b>	<b>0.22</b>	<b>0.91</b>

A large amount of non-current assets was transferred to Property, Plant, and Equipment on June 30, 2024, from Construction Work in Progress. As a result, more depreciation expense was charged compared to the previous period, which is one of the main reasons for the decline in EPS.

SL No.	Particulars	Amount in BDT	
		July 2024 to December 2024	July 2023 to December 2023
<b>33.</b>	<b>Net Assets Value (NAV) Per Share</b>		
	Total Assets	54,289,405,082	53,185,508,321
	Total Liabilities	33,271,399,477	31,645,931,982
	Net Assets	21,018,005,605	21,539,576,339
	No of shares	234,000,000	234,000,000
	<b>Net Assets Value (NAV) Per Share</b>	<b>89.82</b>	<b>92.05</b>
<b>33a</b>	<b>Net Assets Value (NAV) Per Share</b>		
	Total Assets	39,074,436,720	38,452,129,354
	Total Liabilities	24,844,629,914	23,799,823,138
	Net Assets	14,229,806,805	14,652,306,216
	No of shares	234,000,000	234,000,000
	<b>Net Assets Value (NAV) Per Share</b>	<b>60.81</b>	<b>62.62</b>
<b>34.</b>	<b>Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018: Reconciliation of Net operating cash flow under Indirect Method:</b>		
	<b>Net profit before tax</b>	(35,429,599)	361,681,936
	Workers profit participation fund	5,113,591	13,353,717
	Interest & other income	(8,297,053)	(13,785,867)
	Financial expenses	175,642,071	48,891,937
	Depreciation	336,316,059	279,089,055
	Increase/(Decrease) in inventory	127,135,604	(377,308,117)
	Increase/(Decrease) in receivables	(379,484,240)	(317,997,965)
	Increase/(Decrease) in advance deposit & prepayments	206,466,154	73,776,987
	Increase/(Decrease) in payable	596,047,007	658,488,324
	Increase/(Decrease) in accrued expenses	1,946,213	21,578,798
	Income taxes paid	(28,090,238)	(120,185,674)
	<b>Net cash flow from operating Activities</b>	<b>997,365,568</b>	<b>627,583,130</b>
<b>34.1</b>	<b>Net operating cash flow per share</b>	<b>4.26</b>	<b>2.68</b>
<b>34.a</b>	<b>Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018: Reconciliation of Net operating cash flow under Indirect Method:</b>		
	<b>Net profit before tax</b>	102,271,817	267,074,338
	Workers profit participation fund	5,113,591	13,353,717
	Interest & other income	(8,297,053)	(13,785,867)
	Financial expenses	100,343,492	30,114,862
	Depreciation	288,063,516	140,087,628
	Increase/(Decrease) in inventory	33,099,651	25,140,722
	Increase/(Decrease) in receivables	91,710,074	(18,326,019)
	Increase/(Decrease) in advance, deposit & prepayments	206,710,542	75,324,392
	Increase/(Decrease) in payable	(34,727,731)	32,349,600
	Increase/(Decrease) in accrued expenses	(8,268,930)	1,520,050
	Income taxes paid	(28,090,238)	(120,185,674)
	<b>Net cash flow from operating activities</b>	<b>747,928,731</b>	<b>432,667,747</b>
<b>34a.1</b>	<b>Net operating cash flow per share</b>	<b>3.20</b>	<b>1.85</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary